↓ Skip to main content

Dove Medical Press

Article Metrics

Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study

Overview of attention for article published in Drug Design, Development and Therapy, May 2017
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
38 Mendeley
Title
Atorvastatin, a double weapon in osteoporosis treatment: an experimental and clinical study
Published in
Drug Design, Development and Therapy, May 2017
DOI 10.2147/dddt.s133020
Pubmed ID
Authors

nagla El-Nabarawi, Mohamed El-Wakd, Mostafa Salem

Abstract

The aim of this study was to evaluate the effect of atorvastatin on the bone formation and resorption markers in ovariectomized rats (experimental study), and to study its effect on the bone mineral density (BMD) in postmenopausal osteoporotic women (clinical study). The study involved experimental and clinical aspects. In the experimental aspect, 42 female Wistar rats were divided into five groups: Group I (n=6; sham-operated), Group II (n=6; 1 mL of carboxymethyl cellulose [CMC] was administered orally), Group III (n=6; 20 mg/kg orally of atorvastatin was administered), Group IV (n=12; untreated ovariectomized [OVX] rats and served as a model of osteoporosis [OP]) and Group V (n=12; 20 mg/kg orally of atorvastatin was administered to ovariectomized rats). After 4 weeks, serum acid phosphatase, alkaline phosphatase, osteocalcin, total calcium and inorganic phosphorus were assessed. Then, 3 µm thickness lumbar and femur sections were examined using a light microscope to assess cortical thickness, trabecular area, numbers of osteoblasts and osteoclasts. In the clinical aspect, 85 post-menopausal osteoporotic females with recently detected hyperlipidemia participated in the study. Atorvastatin 40 mg/day, calcium carbonate 500 mg/day and vitamin D 800 international units were given to all patients for a period of 18 months. BMD was measured at the start and at the end of the study by dual-energy X-ray absorptiometry (DEXA). In the experiment aspect, the biomarkers of bone remodeling were notably elevated in the OVX group. Administration of atorvastatin produced a significant decrease in the level of these bone metabolic markers. Atorvastatin significantly ameliorates osteoporotic changes induced by ovariectomy. In the clinical aspect, after 18 months the DEXA showed improvement in the T-score for the three measured zones; however, these changes were statistically significant only in the femoral neck area. Atorvastatin was able to decrease the rate of bone metabolism and increase osteogenic activity. It has dual mode of action; both anabolic and antiresorptive effect on bone. This lipophilic statin member may act as a double weapon drug.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 3%
Unknown 37 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 18%
Student > Master 7 18%
Other 4 11%
Student > Postgraduate 3 8%
Researcher 3 8%
Other 5 13%
Unknown 9 24%
Readers by discipline Count As %
Medicine and Dentistry 15 39%
Pharmacology, Toxicology and Pharmaceutical Science 3 8%
Biochemistry, Genetics and Molecular Biology 2 5%
Agricultural and Biological Sciences 1 3%
Nursing and Health Professions 1 3%
Other 2 5%
Unknown 14 37%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 May 2017.
All research outputs
#7,711,251
of 9,957,452 outputs
Outputs from Drug Design, Development and Therapy
#651
of 1,159 outputs
Outputs of similar age
#188,237
of 263,572 outputs
Outputs of similar age from Drug Design, Development and Therapy
#23
of 42 outputs
Altmetric has tracked 9,957,452 research outputs across all sources so far. This one is in the 12th percentile – i.e., 12% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,159 research outputs from this source. They receive a mean Attention Score of 3.8. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 263,572 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.